Biosimilar Manufacturing solution center

  1. mRNA LNPs Drive Safe, Effective Repeat Dosing In Disease Models 6/19/2026

    Well-designed lipid nanoparticles enable safe, efficient delivery. OVA-based models show how formulation choices shape efficacy, safety, and anti-tumor outcomes in melanoma research.

  2. Discover A System That Can Be Used With Various Cell Culture Media 6/19/2026

    Evolving CAR T cell therapies are raising the bar for manufacturing. Advances in cell expansion and the shift to serum-free media are redefining how scalable, future-ready processes are designed.

  3. Developing CAR T Therapies With A Cell Therapy Manufacturing Platform 6/19/2026

    Advances in CAR T cell engineering are expanding clinical potential, but manufacturing complexity limits scale. Integrated, automated workflows offer a path to consistent and efficient production.

  4. A Practical Guide To Autologous CAR T Manufacturing 6/19/2026

    Early process decisions shape scalability, consistency, and compliance in autologous CAR T manufacturing. Learn where variability emerges across the workflow and how to plan ahead.

  5. Achieving High CAR T Cell Transduction Using An Automated Platform 6/19/2026

    Automation is reshaping CAR T manufacturing. A modular, closed approach with digital integration supports efficient workflows while maintaining critical functional performance under GMP conditions.

  6. Accelerating Autologous CAR T Cell Expansion With Automation 6/19/2026

    Scaling CAR T manufacturing demands high expansion without exhaustion. Examine integrated, semi-automated approaches with digital traceability that can improve consistency and preserve cell function.

  7. Evaluating CAR T Cell Therapy Processing 6/19/2026

    Serum-free media is reshaping CAR T manufacturing. Gain insight into how media-agnostic platforms offer the flexibility to adapt workflows without re-optimization, helping teams streamline processes.

  8. The Scale-Up Of A Transient rAAV8 Production Process 6/18/2026

    New approaches to suspension cell culture and process scaling enable consistent, high-titer rAAV production. Gain insight into a clearer path to scalable manufacturing for gene therapy pipelines.

  9. Unlocking The Full Potential Of Antibody-Drug Conjugates (ADCs) 6/15/2026

    ADCs are evolving rapidly. Gain insight into how success now hinges on managing complexity, delivery, and scalability to turn promising designs into viable therapeutic products.

  10. ADC Manufacturing: Practices, Challenges, And The Road Ahead 6/15/2026

    ADCs are advancing quickly, but manufacturing complexity is rising just as fast. Key challenges in scale-up, regulation, and costs are reshaping how the next generation of therapies will be delivered.